California made a big bet on producing its own insulin. There’s no ‘date certain’ for delivery
California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...
The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. “Merilog ...
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.
Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...
Sanofi’s cardiovascular (CV) and central nervous system (CNS) therapies have gained traction, supported by partnerships.
The study will compare drug effects on glucose levels ... Additional support in the form of donation of supplies comes from the National Diabetes Education Program, Sanofi-Aventis, Bristol-Myers ...
Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback